| Literature DB >> 28018219 |
Shatadal Ghosh1, Abhijit Sarkar1, Sudip Bhattacharyya1, Parames C Sil1.
Abstract
Silymarin (SMN) has been shown to possess a wide range of biological and pharmacological effects. Besides, SMN has antioxidant and free radical scavenging activities. Thioacetamide (TAA) is a well-documented liver toxin that requires oxidative bioactivation to elicit its hepatotoxic effect which ultimately modifies amine-lipids and proteins. Our study has been designed in a TAA exposed mouse model to investigate whether SMN could protect TAA-induced oxidative stress mediated hepatic and renal damage. Results suggest that TAA generated reactive oxygen species (ROS), caused oxidative stress and induced apoptosis in the liver and kidney cells via JNK as well as PKC and MAPKs signaling. All these detrimental effects of TAA could, however, be suppressed by SMN which not only scavenged ROS but also induced PI3K-Akt cell survival pathway in the liver and prevented apoptotic pathways in both the organs. Histological studies, collagen staining and DNA fragmentation analysis also supported our results. Combining, we say that SMN possess beneficial role against TAA mediated hepatic and renal pathophysiology.Entities:
Keywords: MAPKs; PI3k/Akt; apoptosis; kidney; liver; oxidative damage; silymarin; thioacetamide
Year: 2016 PMID: 28018219 PMCID: PMC5156955 DOI: 10.3389/fphar.2016.00481
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Effect of TAA and SMN on liver marker enzymes.
| Parameters | Cont | SMN | TAA | TAA+SMN |
|---|---|---|---|---|
| ALP | 14.45 ± 1.25 | 16.36 ± 1.31 | 39.12 ± 2.64a | 18.35 ± 1.51b |
| ALT | 58.67 ± 1.51 | 69.23 ± 1.67 | 140.04 ± 2.31a | 81.75 ± 2.11b |
| AST | 132.78 ± 4.15 | 145.65 ± 5.43 | 361.73 ± 7.75a | 213.47 ± 7.91b |
| LDH | 172.35 ± 5.35 | 194.63 ± 6.19 | 510.74 ± 9.68a | 247.65 ± 7.27b |
| Albumin | 3.42 ± 0.06 | 3.31 ± 0.07 | 2.12 ± 0.10a | 2.97 ± 0.09b |
| NO production | 28.05 ± 0.76 | 29.03 ± 0.81 | 71 ± 1.78a | 38 ± 1.13b |
| FRAP | 100 ± 8,91 | 100 ± 13.67 | 100 ± 67.37a | 100 ± 17.25b |
Effect of TAA and SMN on renal markers.
| Parameters | Cont | SMN | TAA | TAA+SMN |
|---|---|---|---|---|
| Creatinine (mg/dl) | 0.56 ± 0.01 | 0.58 ± 0.01 | 1.79 ± 0.036a | 0.79 ± 0.031b |
| BUN (mg/dl) | 19.12 ± 0.35 | 20.13 ± 0.36 | 36.46 ± 0.69a | 23.03 ± 0.39b |
Effect of TAA and SMN on antioxidant enzymes activities in liver tissue.
| Parameters | Cont | SMN | TAA | TAA+SMN |
|---|---|---|---|---|
| SOD | 164.59 ± 2.73 | 165.59 ± 3.51 | 115.25 ± 4.37a | 144.60 ± 3.29b |
| CAT | 154.54 ± 3.03 | 156.51 ± 3.02 | 87.45 ± 3.39a | 129.14 ± 2.68b |
| GPx | 84.93 ± 1.25 | 86.23 ± 1.88 | 48.61 ± 2.13a | 75.73 ± 1.77b |
| GR | 40.46 ± 0.74 | 40.15 ± 0.98 | 18.99 ± 1.52a | 28.14 ± 1.41b |
| GST | 3.05 ± 0.05 | 2.84 ± 0.06 | 1.37 ± 0.08a | 2.56 ± 0.07b |
| MDA | 2.59 ± 0.05 | 2.57 ± 0.06 | 5.34 ± 0.15a | 3.13 ± 0.16b |
| Redox ratio | 9.11 ± 0.37 | 8.98 ± 0.38 | 4.46 ± 0.23a | 7.36 ± 0.26b |
Effect of TAA and SMN on antioxidant enzymes activities in kidney tissue.
| Parameters | Cont | SMN | TAA | TAA+SMN |
|---|---|---|---|---|
| SOD | 175.45 ± 5.69 | 170.37 ± 5.47 | 129.34 ± 6.71a | 161.37 ± 7.36b |
| CAT | 132..56 ± 4.61 | 133.61 ± 4.54 | 76.32 ± 4.03a | 117.59 ± 5.71b |
| GPx | 125.91 ± 6.13 | 122.03 ± 5.51 | 69.23 ± 4.81a | 108.15 ± 5.13b |
| GR | 115.35 ± 4.12 | 109.68 ± 4.05 | 67.36 ± 3.79a | 98.26 ± 4.21b |
| GST | 3.09 ± 0.06 | 2.98 ± 0.07 | 1.99 ± 0.08a | 2.65 ± 0.09b |
| MDA | 2.51 ± 0.1 | 2.67 ± 0.14 | 6.31 ± 0.41a | 3.21 ± 0.47b |
| GSH | 25.08 ± 1.07 | 26.13 ± 1.09 | 18.32 ± 0.87a | 22.04 ± 0.97b |
| Redox ratio | 32.23 ± 1.25 | 32.06 ± 1.31 | 21.13 ± 1.41a | 28.38 ± 1.46b |
| FRAP | 100 ± 4.53 | 98.65 ± 4.32 | 47.25 ± 5.13a | 89.05 ± 9.33b |
The product size and annealing temperature of the primers used for Fas, Fas L, and actin genes.
| Gene | Oligonucleotides used for real-time polymerase chain reaction (PCR) primer sequence 5′ to 3′ | Annealing temperature (°C) | DNA bases (bp) |
|---|---|---|---|
| Fas | Fp:AGACAGGATGACCCTGAATCTA | 54.7 | 22 |
| Bp:TTCTGCTCAGCTGTGTCTTG | 55.1 | 20 | |
| Fas L | Fp:ATATGGGCCCACAGCAG | 54.9 | 17 |
| Bp:AGACTCTCATTCAAGACAATATTCC | 52.4 | 25 | |
| Actin | Fp:ACATTGGCATGGCTTTGTTT | 53.8 | 20 |
| Bp:GTCCTCAGCCACATTTGTAGA | 54.5 | 21 |